Get access

CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma

Authors

  • William A. Kanner,

    Corresponding author
    1. Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA
      William A. Kanner, MD, Department of Pathology, University of Virginia Health System, PO Box 800214, 1215 Lee Street, Office 3036, Charlottesville, VA 22908-0214, USA
      Tel: 434-982-4404
      Fax: 434-924-8767
      e-mail: wk3g@virginia.edu
    Search for more papers by this author
    • *

      The first two authors contributed equally to this paper.

  • Louis B. Brill II,

    1. Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
    • *

      The first two authors contributed equally to this paper.

  • James W. Patterson,

    1. Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author
  • Mark R. Wick

    1. Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA
    Search for more papers by this author

William A. Kanner, MD, Department of Pathology, University of Virginia Health System, PO Box 800214, 1215 Lee Street, Office 3036, Charlottesville, VA 22908-0214, USA
Tel: 434-982-4404
Fax: 434-924-8767
e-mail: wk3g@virginia.edu

Abstract

Background: Atypical fibroxanthoma (AFX) is a pleomorphic spindle cell lesion of the skin; it is considered in the differential diagnosis with spindle cell malignant melanoma (MM) and sarcomatoid carcinoma/spindle cell squamous cell carcinoma (SCC). An optimum approach has yet to fully emerge with respect to the immunohistochemical discrimination of these lesions.

Methods: Departmental archives from 1978 onwards were searched for clinicopathologically confirmed cases of AFX, MM and SCC. Immunostains for CD10, CD99 and p63 were performed in each case. Scored staining results were analyzed using Fisher's Exact Test.

Results: Twenty-seven of 31 cases of AFX were positive for CD10, as compared with 3 of 22 SCCs and 0 of 20 MMs. CD10 positivity was preferentially associated with the diagnosis of AFX (p < 0.001). p63 reactivity was observed in 15/22 cases of SCCs, 5/31 AFXs and 1/20 MMs. CD99 reactivity was observed in 3/31 cases of AFX, 2/22 SCCs and 3/20 MMs.

Conclusion: CD10 positivity is relatively specific in this context for the diagnosis of AFX. Its utility is enhanced when only strong, diffuse membranocytoplasmic staining is considered as a positive result. In contrast to prior reports, p63 was not found to be highly sensitive for SCC. Similarly, CD99 showed no preferential staining of any single diagnostic group of lesions.

Kanner WA, Brill LB, Patterson JW, Wick MR. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.

Get access to the full text of this article

Ancillary